Literature DB >> 7546909

Frequent detection of antibodies against HTLV antigens in patients with AIDS-related non-Hodgkin lymphoma.

G Zehender1, L Meroni, S Piconi, C De Maddalena, C Parravicini, M Clerici, A L Ridolfo, M Moroni, M Galli.   

Abstract

We studied the prevalence of anti-HTLV-I/II antibodies in 22 patients with AIDS-related non-Hodgkin lymphoma (NHL), 453 HIV-1-infected patients without lymphoma (194 of whom were diagnosed as having AIDS), and 6 HIV-1-positive and 75 HIV-1-negative patients with Hodgkin lymphoma. The frequency of serological reactivity against HTLV antigens was significantly higher in the AIDS patients with lymphoma than in those without (8 of 22, 36.4% vs. 20 of 194, 10.3%-p = 0.0027). One of the HIV-1-positive and none of the HIV-1-negative patients with Hodgkin lymphoma showed anti-HTLV-I/II reactivity. Four of the eight seropositive NHL patients showed antibodies directed against HTLV-II recombinant antigens when tested for serological discrimination in a Western blot assay. A PCR study of PBMCs from the only patient with NHL still alive at the time of the study showed HTLV-II-specific sequences in the genomic DNA. These data suggest that HTLV-II or a closely homologous retrovirus infects a high proportion of patients with AIDS-associated NHL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7546909     DOI: 10.1089/aid.1995.11.823

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  2 in total

1.  Human T-cell lymphotropic virus infection in pregnant women in Spain.

Authors:  C Tuset; M Gutiérrez; C Carbonell; T Tuset; V Soriano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

2.  Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy.

Authors:  G Zehender; L Meroni; S Varchetta; C De Maddalena; B Cavalli; M Gianotto; A B Bosisio; C Colasante; G Rizzardini; M Moroni; M Galli
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.